Previous 10 | Next 10 |
Athersys (ATHX): FY GAAP EPS of -$0.11 beats by $0.32.Revenue of $1.27M (+337.9% Y/Y) beats by $0.99M.Press Release For further details see: Athersys EPS beats by $0.32, beats on revenue
Management to host conference call at 4:30 PM EDT today Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights. "Despite a difficult operating environment, Athersys has made meaningful progress ov...
Today, we take an in-depth look at a small-cap concern called Athersys. The stock of this regenerative medicine concern has been range bound for years, but its pipeline seems to be advancing despite pandemic impacts. A full analysis follows below. For further details see: ...
Company will provide business updates during the earnings call and release investor day video segments on Company website Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, March 25, 2021, and...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem ® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial p...
Athersys' (ATHX) chairman & CEO Dr. Gil Van Bokkelen stepped down, effective immediately, B.J. Lehmann is appointed as interim CEO while Dr. Ismail Kola is named as board chairman.The company's investor day scheduled for today now stands postponed.Board is commencing a...
Gil Van Bokkelen to Step Down as Chairman and CEO; B.J. Lehmann Appointed Interim CEO Board Initiating Search for Permanent Successor; Ismail Kola appointed Chairman of the Board Company Postpones Investor Day Athersys, Inc. (Nasdaq: ATHX), a regenerative med...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
MultiStem partners battle in nasty board fight. Japan Results in Stroke and ARDS 90+% enrolled. BARDA funding for COVID-19 ARDS back in play? For further details see: Update On Athersys - Trying To Read Between The Lines
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...